H.C. Wainwright analyst Andrew Fein views the risk/reward profile on Amarin shares as "highly favorable" into the Reduce-It trial readout this September. The full value of Amarin resides with a successful trial outcome, Fein tells investors in a research note. He says he can "easily justify" a $14 price target with a 100% probability of success for the trial, representing 450% upside. If the trial is a miss, Fein says his price target would be $2, implying "only" 30% downside. He believes Vascepa may become the standard of care following Reduce-It outcome. The analyst keeps a Buy rating on Amarin with a $10 price target.